Krakauer added, "This restructuring exemplifies Cantel's commitment to improved financial performance, especially in light of the recent unprecedented cost increases in raw material and transportation costs being experienced throughout its divisions. These cost increases will clearly have a negative impact on the Company's FY 2008 4th quarter performance. However, despite these increases, we believe various initiatives now being undertaken by our divisions and at corporate headquarters (including the imposition of price increases to our customers) will lead to significant earnings growth in FY 2009 and beyond."
Cantel Medical Corp. is a leading provider of infection prevention and control products in the healthcare market. Our products include specialized medical device reprocessing systems for renal dialysis and endoscopy, dialysate concentrates and other dialysis supplies, disposable infection control products primarily for the dental industry, water purification equipment, sterilants, disinfectants and cleaners, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens.
For further information, visit the Cantel website at http://www.cantelmedical.com.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform
'/>"/>
| SOURCE Cantel Medical Corp. Copyright©2008 PR Newswire. All rights reserved |